Phathom Pharma soars after FDA grants 10-year exclusivity shield for stomach drug

ReutersJun 6, 2025 4:55 PM

View all comments（0）



Shares of drugmaker Phathom Pharmaceuticals PHAT.O rise 134% to near 7-month high of $11

Co's request to the US FDA to update the "Orange Book" has been approved, granting its stomach infection medication, Voquezna, a 10-year exclusivity period

Stock set for its best day on record, if gains hold

The exclusivity period will prevent other firms from making similar versions of Voquezna

Phathom filed a citizen petition to the FDA last year, seeking this exclusivity

This exclusivity was initially granted to other versions of the drug, Voquezna Paks, which contain the same active ingredient as Voquezna

Exclusivity protection will extend through May 3, 2032

Including session's moves, stock up 31% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

Japan and South Korea Stocks Open Lower, Samsung Strike Storm and Higher-Than-Expected Inflation Disrupt Markets

TradingKey - On May 13, the Nikkei 225 Index opened 0.5% lower, while South Korea’s KOSPI Index opened down 1.7% before losses further widened to 3%.

Today’s Market Recap: US Inflation Hits 3-Year Peak as Market Braces for Trump’s China Visit and Fed Leadership Shift

April inflation hit a three-year peak of 3.8%, pressuring the Nasdaq and tech stocks. Markets are further braced by Kevin Warsh’s Fed Chair confirmation, the maintenance of Trump’s 10% global tariffs, and a high-profile U.S. business delegation preparing for a strategic state visit to China.

BigBear.ai Stock Down 26% YTD – Should You Invest in BBAI Stock in 2026? Can the Ask Sage Deal Lead to a Rebound?

TradingKey - BigBear.ai (BBAI) provided a modest first-quarter update on May 5, and BBAI shares have declined about 26% year to date. The company finalized the acquisition of Ask Sage in January, marking its shift away from a services-heavy government contractor to a platform-centric AI company. The

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

TradingKey - Cerebras Systems (CBRS) IPO prices May 13–14 at $125–$135/share. $26–$27B valuation, 20x oversubscribed, $510M revenue, 47% net margin, OpenAI 750MW deal. Everything you need to know.

AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

TradingKey - On May 5 (ET), Advanced Micro Devices (AMD) released its first-quarter fiscal 2026 financial results after the market close. The company reported revenue of $10.253 billion, up 38% year-over-year, exceeding market expectations of $9.89 billion. Non-GAAP earnings per share (EPS) were $1.

Featured Tools